The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance by Hepburn AC et al.
Oncogene (2019) 38:4412–4424
https://doi.org/10.1038/s41388-019-0712-y
ARTICLE
The induction of core pluripotency master regulators in cancers
defines poor clinical outcomes and treatment resistance
A. C. Hepburn1 ● R. E. Steele2 ● R. Veeratterapillay3 ● L. Wilson1 ● E. E. Kounatidou1 ● A. Barnard1 ● P. Berry1 ●
J. R. Cassidy1 ● M. Moad1 ● A. El-Sherif4 ● L. Gaughan1 ● I. G. Mills2,5 ● C. N. Robson 1 ● R. Heer 1,3
Received: 24 August 2018 / Revised: 15 January 2019 / Accepted: 16 January 2019 / Published online: 11 February 2019
© The Author(s) 2019. This article is published with open access
Abstract
Stem cell characteristics have been associated with treatment resistance and poor prognosis across many cancer types. The
ability to induce and regulate the pathways that sustain these characteristic hallmarks of lethal cancers in a novel in vitro
model would greatly enhance our understanding of cancer progression and treatment resistance. In this work, we present
such a model, based simply on applying standard pluripotency/embryonic stem cell media alone. Core pluripotency stem cell
master regulators (OCT4, SOX2 and NANOG) along with epithelial–mesenchymal transition (EMT) markers (Snail, Slug,
vimentin and N-cadherin) were induced in human prostate, breast, lung, bladder, colorectal, and renal cancer cells. RNA
sequencing revealed pathways activated by pluripotency inducing culture that were shared across all cancers examined.
These pathways highlight a potential core mechanism of treatment resistance. With a focus on prostate cancer, the culture-
based induction of core pluripotent stem cell regulators was shown to promote survival in castrate conditions—mimicking
first line treatment resistance with hormonal therapies. This acquired phenotype was shown to be mediated through the
upregulation of iodothyronine deiodinase DIO2, a critical modulator of the thyroid hormone signalling pathway. Subsequent
inhibition of DIO2 was shown to supress expression of prostate specific antigen, the cardinal clinical biomarker of prostate
cancer progression and highlighted a novel target for clinical translation in this otherwise fatal disease. This study identifies a
new and widely accessible simple preclinical model to recreate and explore underpinning pathways of lethal disease and
treatment resistance.
Introduction
One of the most daunting clinical challenges is the man-
agement of treatment-resistant cancer that leads to incurable
lethal disease. Preclinical studies have demonstrated
significant advances in our ability to study aggressive can-
cer in vitro. More recently, 2D and 3D models have yielded
important mechanistic insight and therapeutic targets in
aggressive cancers including establishment of field defining
tumour organoid cultures and patient-derived xenografts
[1–5]. Furthermore, gene expression studies from clinical
data show that transcription signatures associated with stem
cell pathways identify aggressive cancers and inform on
poor outcomes to therapy in a wide range of malignancies
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including breast, glioma, bladder, prostate, lung and ovarian
cancers [6–8]. The ability to recreate these phenotypes
in vitro would allow a new approach to explore under-
pinning pathways of treatment resistance and the drivers
behind aggressive disease.
Previously, a small number of transcription factors
including octamer-binding factor 4 (OCT4/Pou5f1), SRY
box-containing factor 2 (SOX2), and NANOG were iden-
tified as the master regulators of self-renewal and plur-
ipotency of embryonic stem cells (ESCs) [9]. These factors
were subsequently shown to reprogramme somatic cells into
induced pluripotent stem cells (iPSCs) [10, 11] and are
thought to promote lineage plasticity that allows cancer
cells to adapt to growing in distinct sites of the body and to
develop resistance to cancer therapy [5, 12, 13]. Addition-
ally, core stem cell traits namely self-renewal, hyperproli-
feration, suppressed apoptosis, evasion of immune
surveillance and plasticity are often shared by tumours and
moreover co-opted expression of these stem cell master
regulators has been reported in many cancers [14–18].
These discoveries suggest that regulation of ESC identity,
cellular reprogramming and tumorigenesis may share
common pathways controlled by the same core master
regulators [19, 20]. Since reprogramming techniques for
iPSC generation have demonstrated that stem cell culture
contains environmental drivers that induce and maintain
pluripotent factors within associated cells [21], we explored
using this approach to generate a new in vitro model of
inducing stem cell characteristics in human cancer cells.
In this study, we confirm that clinical expression of
pluripotent factors OCT4, SOX2 and NANOG is associated
with treatment resistance and lethal cancers. Then,
describing a new model to induce these factors in vitro, we
reveal treatment resistance pathways across common can-
cers and, as an example in prostate cancer, we uncover a
new treatment target for castration-resistant disease, the
thyroid hormone (TH) pathway.
Results
Expression of pluripotency master regulators
identifies aggressive cancers and disease resistance
As aggressive cancers have been previously shown to be
marked by the expression of a large network of stem cell
genes [6, 7], it was hypothesised they could alternatively be
defined, by proxy, by the expression of just a small number
of core pluripotent master regulators. To investigate if these
master regulators could act as a core signature for clinically
aggressive cancers, we explored an OCT4/SOX2/NANOG
(OSN) expression signature in a large cohort of clinical
cancers (n= 884), comprising of prostate (n= 275), blad-
der (n= 292) and renal cancers (n= 317) (Fig. 1). Speci-
fically, when comparing prostate cancer to ageing prostate
controls, benign prostatic hyperplasia (BPH), we demon-
strated significant upregulation of OSN (n= 67 cancers,
sum OSN score 4.7 ± 2.4 vs n= 34 BPH, sum OSN score
3.03 ± 1.1) (Fig. S2A; t-test, p= 0.0002). This treatment
naïve cohort contained locally advanced or metastatic
prostate cancers that were subsequently treated with
androgen deprivation therapy (ADT) and we showed that
93% of patients co-expressed all three factors (OSN),
indicating the co-operative recruitment of master regulators
promoting a pluripotent phenotype (Fig. 1a, left and middle
panel). We went on to demonstrate that high levels of OSN
expression were associated with a worse prognosis with
Kaplan–Meier analysis indicating that OSNhi prostate
cancer patients (n= 69) had shorter disease specific survival
(DSS) than OSNlo patients (n= 67) (log-rank test,
p= 0.047) (Fig. 1a, right panel). A similar pattern was
demonstrated in the immunostaining of life-threatening
muscle-invasive bladder cancers (MIBC) for OSN which
showed 86% of patients expressed all three factors and
OSNhi patients (n= 63) demonstrated shorter DSS than
OSNlo patients (n= 59) (Fig. 1b; t-test, p= 0.03). We then
explored OSN expression in non-muscle-invasive bladder
cancer (NMIBC) (Fig. S2B-C), where the clinical problem
is the risk of recurrence and in those patients with high-
grade tumours the risk of progression to muscle-invasive
disease. We showed that high levels of OSN expression in
NMIBC patients was associated with higher rates of
recurrent disease (33.3%) and features that leave patients at
high risk of progression to life-threatening muscle-invasive
disease characterised by high histological grade or early
invasive histological stage into the lamina propria invasion
(TNM T-stage 1) (Fig. S2D; OSNhi= 110 and OSNlo= 60,
χ2-test, p= 0.02). Furthermore, the expression of high
levels of OSN in NMIBC was associated with poor
response to intravesical chemotherapy (Fig. S2E). In a
similar fashion, the immunostaining of renal cell cancer
(RCC) patients showed co-expression of all three factors,
albeit at lower levels (54%), and that high level of OSN
expression was associated with (n= 142) shorter progres-
sion free survival (PFS) compared to OSNlo patients (n=
172) (Fig. 1c; t-test, p= 0.001). Additionally, high level of
OSN expression was also associated with higher tumour
stage (Fig. S2F; OSNhi= 142 and OSNlo= 175, χ2-test, p
= 0.04). Collectively, these findings corroborate the asso-
ciation of stem cell pathways signatures with aggressive
disease and that our data specifically demonstrates
that master regulators of stem cell pluripotency (OSN)
correlates with poor survival and treatment resistance in
cancer.
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Pluripotent stem cell factors can be induced in vitro
and characterises aggressive disease
Since reprogramming techniques for iPSC generation have
demonstrated that stem cell culture can generate
environmental drivers that induce pluripotent factors [21],
we explored using this approach an in vitro model of
inducing pluripotent stem cell characteristics. We termed
this culture environment ‘Acquired Pluripotent Stem Cell
Environment (APSCE)’ and comparisons were made to
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Fig. 1 Expression of pluripotency master regulators identifies
aggressive cancers and disease resistance. a Immunohistochemical
analysis of tissue microarrays for prostate cancer demonstrating fre-
quency of OCT4, SOX2 and NANOG expression (left panel), illus-
trative tissue cores of prostate cancer stained for OCT4, SOX2 and
NANOG (OSN) representative of high (OSNhi) and low (OSNlo) levels
of expression (middle panel) and correlation of OSN sum score with
disease-specific survival (DSS) by Kaplan–Meier analysis (right
panel). b Same as a but for muscle-invasive bladder cancer (MIBC).
c Same as b but for renal cancer. Note correlation of OSN sum
score with Progression Free Survival (PFS) by Kaplan–Meier analysis
(right panel)
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culture in conventional serum supplemented “full media”
(FM) (Fig. 2a). Culture of prostate (LNCaP), bladder
(RT112) and renal (Caki-2) cancer cells in APSCE resulted
in tight colonies consisting of smaller cells, morphologi-
cally similar to that of ESCs and iPSCs [22] (Fig. 2b–d).
These characteristic morphological changes were also
associated with stem cell gene expressions. We confirmed
APSCE significantly induced an upregulation in the
expression of OSN in prostate, bladder and renal cancer
cells (Fig. 2e–h). As plasticity is modulated by OSN, and in
turn plasticity of cancers can be characterised by the ability
to undergo EMT, a process that is known to be associated
with aggressive metastatic disease [23–25], we investigated
whether culture in APSCE could also induce EMT. A panel
of markers was investigated including E-cadherin, N-cad-
herin, Slug, Snail and vimentin. Of note, it has been shown
that EMT markers have different roles in different cancers
and therefore we investigated expression of genes repre-
sentative of EMT induction specific to the cell line [26–28].
Indeed, an upregulation in the expression of mesenchymal
markers Snail, Slug, vimentin and N-cadherin was observed
in APSCE (Fig. 2e–g). Additionally, pluripotent stem cell-
like morphology, induction of OSN and EMT expressions,
was also confirmed in breast (MCF7), colon (HCT116) and
lung (H661) cancer cells cultured in APSCE (Fig. S3).
Pluripotent factors drive a core regulatory
transcriptome in cancer
To achieve a greater insight into the pathways recruited
during OSN induction, whole transcriptome analysis using
RNA sequencing was performed in prostate cancer cells,
LNCaP and CWR22Rv1. Following culture in APSCE,
1081 genes were differentially expressed (adj. p value <
0.01) by at least twofold compared to culture in FM (Fig.
3a). Data analysis using HumanCyc and Reactome revealed
deregulation of pathways in APSCE including thyroid
hormone metabolism, extracellular matrix organisation and
Fig. 2 A preclinical model to recreate a stem cell-like aggressive
cancer phenotype. a Schematic of culture details of generation of
Acquired Pluripotent Stem Cell Environment (APSCE). Briefly, can-
cer cells were transferred from culture in their regular serum supple-
mented medium (FM) to culture conditions used for human embryonic
stem cells (ESCs) and induced pluripotent stem cells (iPSCs) as
described in ‘Materials and methods’. Following culture of cancer cells
in APSCE, tight colonies consisting of smaller cells, morphologically
similar to that of ESCs and iPSCs, were observed. b–d Prostate
(LNCaP), bladder (RT112) and renal (Caki-2) cancer cell growth in
serum supplemented medium (FM) and APSCE after 7 days. Of note,
for cells cultured in APSCE, feeder cells were used though no MACS
selection was performed. e–g Stemness (OCT4, SOX2, NANOG) and
mesenchymal (vimentin, Snail, Slug, N-cadherin) gene expression was
measured by quantitative PCR (qPCR) following culture in FM vs
APSCE in LNCaP, RT112 and Caki-2 cells. Data represents at least
three independent experiments ± SEM (*denotes p-value < 0.05). Of
note, EMT characterisation studies were carried out without feeders in
APSCE to avoid any mesenchymal cell contamination. h Western blot
analysis demonstrating OCT4, SOX2 and NANOG protein expression
following culture in FM and APSCE in LNCaP, RT112 and Caki-2
cells, using α-tubulin as loading control
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degradation, collagen biosynthesis, integrin cell surface
interactions, histone modifications (Fig. 3b). As an
external validation set, RNA sequencing was also per-
formed in bladder cancer cells, RT112, and following
culture in APSCE 851 genes were differentially expressed
(adj. p value < 0.01) by at least twofold compared to
culture in FM (Fig. S4A). Common characteristics that
were significantly altered in APSCE of both prostate and
bladder cancer cells were identified, including shared
metabolism of lipids and lipoproteins pathways (including
genes involved in cholesterol biosynthesis and
SREBP1 signalling) (Fig. S4B, p < 0.05) and a shared
regulatory signature of differentially expressed genes that
included COL3A1 (collagen biosynthesis), COL16A1
(extracellular matrix organisation and integrin cell surface
interactions), DIO2 (thyroid hormone pathway), FBN1
(extracellular matrix organisation), FOS, ID1, ID3, ID4
and IGFBP3 (Insulin growth factor pathway). (Fig. S4A).
We went on to validate this core regulatory signature by
confirming upregulation or downregulation of these tran-
scripts in prostate, bladder, renal, breast, colon and lung
cancer cells (Fig. 3c).
Pluripotent stem cell factors are associated with
clinical treatment resistance
Poor outcomes in cancer treatment reflects either inherent
aggressiveness of the cancer and/or acquired resistance to
treatment. Specifically in prostate cancer, androgens func-
tioning through the androgen receptor (AR) are central to
both initiation and disease progression [29]. Thus, androgen
deprivation therapy (ADT) is the mainstay for advanced
prostate cancer patients, but in time there is inevitable dis-
ease progression and development of lethal treatment-
resistant prostate cancer. Using the clinical biochemical
measure of prostate specific antigen (PSA) for treatment
response, 70% of OSNhi prostate patients went on to
develop resistance to ADT in 1.9 years (n= 58) compared
to 54% of OSNlo patients (n= 55) (Fig. 4a; t-test, p=
0.0016). Also, OSNlo patients had a lower PSA nadir and
showed a greater fold reduction (PSA at presentation/PSA
nadir), indicative of a better response to ADT (Fig. S5A).
Having confirmed castration levels of testosterone in the
APSCE to be comparable with the conventional model of
ADT in steroid-depleted medium (SDM) [30, 31] (Fig. 4b),
Fig. 3 Pluripotent factors drive a
core regulatory transcriptome in
cancer. a Venn diagrams of
genes demonstrating ≥2-fold up-
and downregulation following
culture in APSCE in prostate
cancer cells (LNCaP and
CWR22Rv1). The overlapping
up- and downregulated genes in
prostate cancer cells are noted. b
Table of pathways most
significantly altered following
culture of prostate cancer cells
(LNCaP and CWR22Rv1) in
APSCE. c Heatmap
demonstrating transcript
expression of core regulatory
signature in APSCE compared
to culture in FM in prostate
(LNCaP), bladder (RT112),
renal (Caki-2), breast (MCF7),
colon (HCT116) and lung
(H661) cancer cells.
Measurements made by real
time PCR. Data represents at
least three independent
experiments and is Log2
transformed
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we noted a paradoxical upregulation of AR target gene
expression following culture of castration-resistant prostate
cancer cells CWR22Rv1 in APSCE (Fig. 4c, Fig. S5B).
Specifically, we confirmed functional activity of AR
through increased expression of downstream readouts of
PSA, TMPRSS2, KLK2 and NKX3.1 transcripts. A similar
induction was also seen in classically hormone-dependent
LNCaP cells when cultured in APSCE, which were now
able to be maintained without becoming abortive colonies
in the absence of androgens (Fig. S5C-D). These behaviours
are the hallmarks of castration-resistant prostate cancer
underpinned by bypass signalling pathways characterised
through various mechanisms of aberrant AR activation [32].
Acquired pluripotent pathways drive castration-
resistant prostate cancer independent of
conventional AR signalling
Recently, multiple AR splice variants (AR-Vs) that lack the
ligand-binding domain (LBD) have been described to be
constitutively active in the absence of androgen ligand and
contribute to the development of castration-resistant pros-
tate cancer (CRPC) [33, 34]. Reports suggest AR-Vs can
regulate canonical AR target genes as well as their own
distinct transcriptome and as they lack the LBD they evade
inhibition by antiandrogens [35, 36]. This was validated in
the CWR22Rv1 model expressing both full-length AR (AR-
FL) and AR-Vs, whereby AR target genes were still
expressed following knockdown of AR-FL with siRNA
targeting exon 7 (siEX7) (Fig. 5a–f). Since we found
APSCE, a castrate environment, was associated with para-
doxical upregulation of AR target genes, we speculated this
was driven by AR-Vs. To confirm this, we assessed AR
target gene expression following depletion of AR-V7, the
predominant constitutively expressed variant in
CWR22Rv1, with siRNA targeting cryptic exon 3 (siCE3)
(Fig. 5c–f). Depletion of AR-V7 resulted in increased
expression of PSA and KLK2 in APSCE suggesting
regulation by low level AR-FL activity. Thus, we next
assessed depletion of all AR species with siRNA against
exon 1 (siEX1) to target AR-FL and AR-Vs (Fig. 5b, c and
f). As anticipated, siEX1 decreased AR target gene
expression in FM and SDM (Fig. 5d–f, Fig. S6A-B).
Intriguingly, we still observed upregulation of PSA and
KLK2 in APSCE (Fig. 5d–f). Cytoplasmic/nuclear fractio-
nation studies demonstrated absence of AR from the
respective cellular compartments and no binding to chro-
matin following siEX1, providing further confirmation of
effective AR knockdown (Fig. S6C). Additionally, treat-
ment with ENZ following siEX1, to further inhibit possible
low levels of AR-FL below our sensitivity for detection,
also did not reduce PSA expression below basal level (Fig.
S6D). Taken together, these findings suggest alternative
non-AR pathways are being recruited in this environment to
regulate AR target gene expression. However, we did
observe decreased TMPRSS2 and NKX3.1 levels following
depletion of all AR and AR-V7 alone (Fig. S6A-B),
demonstrating the differential effect of APSCE on down-
stream reporters of AR activity and that AR signalling may
still be an active component in this environment.
Because OCT4, SOX2 and NANOG are considered to be
master regulators of the pluripotent state of ESCs and iPSCs
and their induction was shown in APSCE, we asked whe-
ther these factors were required for the stem cell-like
inductions. We performed knockdown studies in prostate
cancer cells using siRNA against all three factors (siOSN)
and confirmed downregulation of the cardinal biomarkers of
prostate cancer progression (PSA and KLK2) in FM (Fig.
S7A). APSCE media had much higher levels of induced
OSN and it was not possible to achieve knockdown with
similar concentrations of siRNA in this background of
competing upregulation from the environment
(Fig. S7B-D).
Next, we proceeded to identify those non-AR pathways
recruited in APSCE by performing whole transcriptome
analysis using RNA sequencing (RNA-Seq) in
Fig. 4 APSCE recreated phenotypes associated with clinical treatment
resistance in castration-resistant prostate cancer. a Comparison of OSN
expression and development of castration-resistant prostate cancer
(CRPC) (t-test, p= 0.0016). b Measurement of testosterone (T) levels
in FM, steroid-depleted medium (SDM) and APSCE medium
including in water (CTRL). c Expression of PSA, KLK2, TMPRSS2
and NKX3.1 was measured by qPCR in CWR22Rv1 cells cultured in
FM, SDM and APSCE. Data is represented as fold change of FM
experimental arm. Data represents at least three independent experi-
ments ± SEM
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CWR22Rv1 cells following knockdown with siEX1 in FM
and APSCE. The observed changes in AR regulated target
gene expression in APSCE were similarly confirmed (Fig.
S8A). Knockdown with siEX1 in APSCE resulted in 1253
genes significantly altered (adj. p value < 0.01) by at least
twofold, with 637 upregulated and 616 downregulated
genes (Fig. 6a, Fig. S8B). Forty-five percent of genes
upregulated in APSCE in CWR22Rv1 cells were sig-
nificantly affected by knockdown with siEX1. Interestingly,
DIO2 was upregulated following siEX1 knockdown (Fig.
6b), also shown to be upregulated in prostate and bladder
cancer APSCE (Fig. 3a and Fig. S4A). Furthermore,
PARP8, TNFRSF19, FAM13A and GDF15 were also sig-
nificantly altered following siEX1 knockdown (Fig. 6b),
also seen to be upregulated in APSCE in prostate LNCaP
cells (Fig. 3a). As shown in Fig. 6c, d, the identified genes
were indeed upregulated or downregulated in APSCE fol-
lowing siEX1 knockdown. Importantly, DIO2, an iodo-
thyronine deiodinase, plays a critical role in modulating
thyroid hormone (TH) signalling. Deiodinase 2 (DIO2)
catalyses the conversion of the prohormone thyroxine (T4)
to the biologically active TH, triiodothyronine (T3), thus
enhancing thyroid hormone signalling [37]. TH functions,
important for growth, development and metabolism, are
Fig. 5 Acquired pluripotent pathways drive castration-resistant prostate cancer independent of conventional AR signalling. a Diagram illustrating
the exons of the androgen receptor (AR) and variants (AR-Vs) that siEX1, siEX7 and siCE3 target. NTD, N-terminal domain; DBD, DNA-binding
domain; LBD, ligand-binding domain; CE, Cryptic exon. b Expression of AR was measured by qPCR following knockdown of AR-FL (siEX7),
AR-V7 (siCE3) and all AR (siEX1) in CWR22Rv1 cells cultured in FM, SDM and APSCE. Data is represented as fold change of siCTRL
experimental arm. Data represents at least three independent experiments ± SEM. c Same as in b but measurement of AR-V7 expression. d Same
as in c but measurement of PSA expression (*denotes p-value < 0.05). e Same as in c but measurement of KLK2 expression. f Resultant lysates
from samples in b, c, d and e were subjected to western blot analysis to measure AR and PSA expression. AR-N20 antibody was used to detect
both AR-FL and AR-Vs and α-tubulin was used as loading control
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mediated through nuclear thyroid hormone receptors con-
trolling the expression of target genes directly or indirectly
through activation of ERK1/2 MAPK pathway, also known
promoter of aggressive phenotypes in prostate cancer [38].
Indeed, increased pERK levels were observed in APSCE
(Fig. 6e). Furthermore, knockdown of DIO2 in APSCE in
CWR22Rv1 cells resulted in decreased PSA expression
(Fig. S9A-B). Tissue expression of DIO2 also demonstrated
utility across a prostate cancer cohort based on hormone
treated prostate cancer patients (Fig. S9C). Additionally,
treatment with DIO2 inhibitor, iopanoic acid (IOP, 50 µM),
at a concentration reported to inhibit iodothyronine binding
to the nuclear TH receptor [39], resulted in decreased PSA
and TH targets, β-catenin and pERK, expression (Fig. 6f,
g). Thus, these data implicate this pathway in castration
resistance in prostate cancer.
Discussion
Identification of the stem cell regulatory pathways under-
pinning treatment resistance that leads to incurable lethal
Fig. 6 APSCE identifies the thyroid hormone signalling network as a
target to overcome castration resistance in prostate cancer. a Venn
diagram demonstrating genes upregulated in APSCE and up- or
downregulated following AR depletion with siEX1 in APSCE in
CWR22Rv1 cells. b Top seven up- and downregulated genes in
APSCE and following AR depletion with siEX1 in APSCE in
CWR22Rv1 cells (where CGA, Chorionic Gonadotrophin subunit
Alpha). c Validation of downregulated genes in the APSCE and fol-
lowing AR depletion with siEX1 by qPCR analysis of
CWR22Rv1 cells after AR depletion with siEX1 in FM and APSCE.
Data is represented as fold change of FM siCTRL experimental arm.
Data represents at least three independent experiments ± SEM. d Same
as in c but validation for upregulated genes. e Western blot analysis
measuring p-ERK expression in CWR22Rv1 cells cultured in FM and
APSCE. Total ERK (ERK1/2) was used as loading control. f Effect of
DIO2 inhibitor, iopanoic acid (IOP, 50 µM) for 24 h on PSA and β-
catenin expression in CWR22RV1 cells in APSCE. g Western blot
analysis measuring PSA and p-ERK expression following treatment of
CWR22Rv1 cells with IOP (50 µM) for 24 h in APSCE. Total ERK
(ERK1/2) was used as loading control
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disease could identify actionable therapeutic targets to
overcome this major clinical problem. Here, we describe a
preclinical model that recapitulates the aggressive and stem
cell-like phenotypes seen in cancer using a novel applica-
tion of pluripotency enhancing culture technology. This
model exhibited inducible upregulation of a stem cell gene
expression signature characterised by key regulators of
pluripotency and associated with aggressiveness and poor
cancer survival in prostate, breast, bladder, lung, colorectal
and renal cancer. A shared regulatory transcriptome acti-
vated in this model across a number of cancers was also
identified, highlighting a common utility targeted treatment.
Using prostate cancer as an exemplar, we showed that
acquisition of pluripotent master regulators drove castration
resistance independent from conventional AR related sig-
nalling and uncovered the TH pathway as a new treatment
target for castration-resistant disease.
Our confirmation of the clinical expression of OSN in
local tumours and its correlation with lethal metastatic
disease, points to a mechanism within primary tumour
biology that potentially promotes metastatic initiation.
Cancer cells expressing stem cell signatures have been
detected in blood and subsequently demonstrated as having
the capacity to generate metastasis [40, 41]. The micro-
environment and environmental cues, such as hypoxia, can
induce stem cell signatures resulting in the acquisition of
invasive and migratory phenotypes [12, 42, 43]. Moreover,
pluripotency factors have been shown to be mediators of
plasticity of key microenvironmental cell players and of
enhanced ECM production leading to metastatic niche for-
mation and metastasis [44].
In APSCE, induction of pluripotent stem cells factors
was associated with reprogramming of AR regulated gene
expression independent of AR and recruitment of alter-
native pathways. Recently, a growing body of evidence has
reported a role for NANOG and SOX2 in promoting cas-
tration resistance [5, 13, 45, 46]. Notably, NANOG was
demonstrated to reprogramme prostate cancer cells by
repressing the AR signalling axis and activating its own
distinct transcriptional programme as well as engaging that
of others such as MYC, leading to acquisition of a
castration-resistant stem cell-like state [13]. Moreover,
SOX2 was identified as a mediator of lineage plasticity,
specifically neuroendocrine transdifferentiation, which was
associated with decreased AR dependency and acquisition
of antiandrogen enzalutamide resistance [5]. There is now
increasing recognition of phenotypic shifts occurring in
metastatic cancers following treatment with AR antagonists
resulting in the development of highly lethal, drug-resistant
castration-resistant disease such as neuroendocrine (NE)
prostate cancer characterised by non-reliance on AR. Fur-
thermore, models of AR-null phenotypes have demon-
strated sensitivity to blockade of AR bypass pathways such
as FGF/MAPK [47]. Our model did not recreate NE dif-
ferentiation and for those studies other models are more
appropriate [48]. It also remains unclear what drives PSA
expression in this model, and other prime candidates such
as glucocorticoid receptor and progesterone receptor nor
their canonical downstream reporters were enriched in the
RNA sequencing analysis in APSCE. Androgen hypersen-
sitivity may also be a possible mechanism of resistance in
APSCE since decreased levels of other downstream repor-
ters of AR activity (TMPRSS2 and NKX3.1) were observed
following depletion of all AR forms (full-length and
spliced). Irrespective of these mechanisms, the identified
downstream actionable targets still remain of therapeutic
interest. Although a contribution of OCT4, SOX2 and
NANOG to AR target gene expression was observed in
androgen-dependent conditions, further exploration in
APSCE was not possible due to inability to knockdown all
three factors simultaneously or even individually in this
environment. OCT4, SOX2 and NANOG not only function
together to maintain the pluripotent state of ESCs but they
also positively regulate their own promoters as well as each
other thus forming an interconnected auto- and cross-
regulatory loop [9].
We showed that targeting iodothyronine deiodinase
DIO2, a critical modulator of the TH signalling pathway,
presents a new approach to overcoming castration-resistant
disease. Preclinical studies have shown androgens and T3
exert similar effects on cell cycle that appear to be mediated
independently through differentially regulated genes [49].
Clinically, epidemiological data suggest a tumour-
promoting effect for TH with T3 levels increased in men
with prostate cancer and associated with higher clinical
stage and risk of disease recurrence in men with localised
prostate cancer [50, 51]. Furthermore, subclinical hypo-
thyroidism measured through elevated thyroid stimulating
hormone (TSH) levels demonstrated a protective effect on
prostate cancer [52, 53] and overt treatment-induced
hypothyroidism was associated with favourable outcome
in RCC [54]. Thus, DIO2 inhibition lays foundations for a
late translational/early phase clinical trial for use of antith-
yroid drugs, such as propylthiouracil, in men with CRPC
and potentially in other cancers too. Additionally, inhibition
of DIO2 has been noted to underlie the elevated plasma
TSH levels associated with treatment using the widely
prescribed cardiac antiarrhythmic drug amiodarone [55] and
repurposing of such approved drugs could be a promising
approach to overcome treatment resistance in prostate can-
cer. However, further understanding the role of DIO2 in
prostate and other cancers requires additional investigation.
Finally, the simple culture-based model we describe in this
report provides an accessibility to research laboratories
worldwide to similarly induce aggressive stem cell char-
acteristics in vitro and enable the exploration of treatment
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resistance mechanisms and associated target discovery in
other cancers.
Materials and methods
Clinical material
All patient tissue samples were used in accordance with
approval granted by the Northumberland, Tyne and Wear
NHS Strategic Health Authority Research Ethics Commit-
tee (reference 2003/11; The Freeman Hospital) and
informed consent from all patients. The demographic
characteristics for the prostate cancer, non-muscle-invasive
bladder cancer, muscle-invasive bladder cancer and renal
cancer patient samples used in this study are described in
Tables S1–4. A total of 34 benign prostatic hyperplasia
(BPH) samples (median age, 64; range 39–70) were also
utilised.
Immunohistochemical analysis
Immunohistochemistry was performed using tissue micro-
arrays containing 0.6-mm cores of BPH, prostate cancer,
bladder cancer, renal cancer and control tissues including
breast, kidney, placenta, ovary, and liver as described [56].
Sections were immunostained with anti-OCT4 1:50 (Milli-
pore, cat. no MABD76), anti-SOX2 1:500 (Millipore, cat.
no MAB4343), anti-NANOG 1:5000 (Cell Signaling, cat.
no 4893) and anti-DIO2 1:500 (Abcam, cat. no ab135711)
and viewed using Aperio CS2 (Leica Biosystems). Human
prostate-derived induced pluripotent stem cells, previously
confirmed to express OCT4, SOX2 and NANOG, were
selected as positive controls (Fig. S1A) [22]. Negative
controls were prepared by incubating without the primary
antibody (Fig. S1B). Immunostaining was reviewed and
scored independently by two uro-pathologists that were
blinded to the clinical data to give average scores of staining
intensities of absent (0), weak (1), moderate (2) or strong
(3). Using a previously validated approach [56, 57], a sum
score for combined expression of all three factors (OCT4,
SOX2 and NANOG, OSN) was calculated to compare high
(OSNhi) and low (OSNlo) levels of OSN expression. Data
was dichotomised at the median sum score (maximum of 9)
with OSNhi ≥ sum score 5 and OSNlo < sum score 5.
Immunofluorescence
Cells were fixed in 4% paraformaldehyde and permeabilised
with 0.1% Triton X-100. Primary antibodies used were anti-
OCT4 1:100 (Millipore), anti-SOX2 1:100 (Millipore) and
anti-NANOG 1:100 (Cell Signaling). Secondary antibodies
used were Alexa Fluor 488 and Alexa Fluor 546 (both at
1:500; Life Technologies). Cells were washed with 1 × PBS
three times between incubations. Cells were mounted using
Vectashield with DAPI mountant (Vector Laboratories)
before being visualised on a confocal laser scanning
microscopy system (Nikon).
Cell culture
Human cancer cell lines LNCaP (derived from localised
prostate cancer), CWR22Rv1 (derived from the human
prostate cancer xenograft CWR22R), RT112 (derived from
transitional cell bladder cancer), Caki-2 (derived from clear
renal cell cancer), MCF7 (derived from breast cancer),
HCT116 (derived from colorectal cancer) and H661
(derived from lung cancer) were obtained from the Amer-
ican Type Culture Collection (Manassas, VA, USA). Cell
lines were authenticated by STR profiling (Newgene). All
cell lines were cultured in RPMI 1640 supplemented with
10% (v/v) foetal calf serum (FCS) and 1% (v/v) L-
glutamine (referred to as FM). All cells were grown at 37 °C
in the presence of 5% CO2. All cell culture reagents were
purchased from Sigma. For studies in androgen-depleted
conditions, cells were cultured in RPMI 1640 supplemented
with 10% (v/v) charcoal-stripped FCS (Biowest) and 1% (v/
v) L-glutamine (referred to as SDM). For studies using
ESC/iPSC culture conditions (referred to as Acquired
Pluripotent Stem Cell Environment, APSCE), cells were
seeded onto gelatin-coated plates with a layer of irradiated
CF-1 mouse embryonic fibroblasts (MEFs, VhBio) in
human ESC/iPSC culture medium (80% (v/v) knockout-
DMEM, 20% knockout serum replacement, 1% (v/v)
GlutaMAX-I Supplement, 1% (v/v) MEM nonessential
amino acids (all from Gibco) and 8 ng/ml FGF2 (Miltenyi
Biotec)). Cancer cells were separated from MEFs using
magnetic activated cell sorting (MACS) for immunomag-
netic selection of Epithelial Cell Adhesion Molecule
(EpCAM/CD326) (Miltenyi Biotec) according to the man-
ufacturer’s instructions. For morphology studies, 100 cells/
well were seeded on six-well plates for both culture in FM
and APSCE conditions. For cells cultured in APSCE, feeder
cells were used though no MACS selection was performed
to avoid any concerns about effects due to epithelial–
mesenchymal transition (EMT) induction. The historically
described use of feeder cells in ESC culture can be aban-
doned in our model as they were redundant in generating
inducing stem cell characteristics. A feeder cell-free method
was also employed whereby cells were seeded onto matrigel
(Corning)-coated plates in mTeSRTM1 culture medium
(Stemcell Technologies). Dihydrotestosterone (DHT) was
used at a final concentration of 10 nM and enzalutamide
(ENZ) was used at a final concentration of 10 μM.
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Androgen level measurement
Quantitation of testosterone was performed in selected
reaction monitoring (SRM) mode. Mass transitions and
optimized MS/MS parameters are given in Table S5. Ana-
lyst® software v1.4.1 (AB SCIEX) was used for SRM, peak
integration, and analyte quantitation. Standard curves were
prepared for testosterone in both tissue culture media and
water in the range 0–20 ng/ml and the limit of detection
(LOD) and lower limit of quantitation (LLOQ) were
established in both matrices. The concentration of testos-
terone was measured in FM, SDM and APSCE media. Peak
areas for these samples were quantified against the external
calibration curves of testosterone (Table S6). Reverse phase
chromatographic separation of testosterone was achieved
using a Perkin Elmer Series 200 LC (Beaconsfield, UK)
equipped with a Luna C8(2) column (3 μm; 20 × 4 mm i.d.)
and SecurityGuard C18 column (4 × 3 mm) (Phenomenex,
UK) maintained at 30 °C and a flow rate of 0.5 ml min−1
using the conditions in Table S7. An API4000 triple
quadrupole LC/MS/MS (Applied Biosystems, USA) was
used for analysis with electrospray ionization (ESI) per-
formed in positive ion mode using nitrogen gas with source
parameters found in Table S8.
RNA extraction, reverse transcription and real time
PCR (qPCR)
Total RNA was extracted using Ribozol™ RNA Extraction
Reagent (Amresco) and reversed transcribed using Moloney
murine leukaemia virus reverse transcriptase enzyme (Pro-
mega) according to the manufacturer’s instructions. Real time
PCR (qPCR) was carried out using Platinum SYBR® green
qPCR SuperMix-UDG (Invitrogen) in 384-well clear optical
reaction plates using the ABI 7900HT qPCR system (Applied
Biosystems) according to the manufacturer’s instructions.
Levels of expression were normalised against housekeeping
gene HPRT1. Primers sequences are described in Table S9.
Western blotting
Cells were lysed and analysed by SDS-PAGE as previously
described [56]. Antibodies used were: anti-AR 1:500 (AR-
N20, Santa Cruz Biotechnology, cat. no sc-816), anti-PSA
1:1000 (DAKO, cat. no A0582), anti-OCT4 1:1000 (Milli-
pore, cat. no MABD76), anti-SOX2 1:1000 (Millipore, cat.
no MAB4343), anti-NANOG 1:1000 (Cell Signaling, cat. no
4893), anti-PARP1/2 1:5000 (Santa Cruz Biotechnology,
cat. no sc-7150), anti-ERK1/2 1:500 (C-9, Santa Cruz Bio-
technology, cat. no sc-514302), anti-phospho-ERK 1:500
(E-4, Santa Cruz Biotechnology, cat. no sc-7383) and anti-α-
tubulin 1:4000 (Sigma, cat. no T9026). For cytoplasmic and
nuclear fractionation experiments, extracts were separated
and prepared using the NE-PER® Nuclear and Cytoplasmic
Extraction Reagents according to the manufacturer’s
instructions (Thermo Scientific). The chromatin fraction was
collected at the end of the extraction.
siRNA transfections
Cells were reverse transfected with siRNA using RNAiMax
(Invitrogen) according to the manufacturer’s instructions at
a final concentration of 25 nM. siRNA sequences used
were: Scrambled 5′-UUCUCCGAACGUGUCACGUdTd
T-3′; AR Exon1 5′-GAAAUGAUUGCACUAUUGAUUd
TdT-3′; AR Exon7 5′-CCAUCUUUCUGAAUGUCC
UdTdT-3′; AR Exon3b 5′-GUAGUUGUGAGUAUCAU-
GAdTdT-3′; OCT4 5′-GUGCAGGCCCGAAAGAGAAU
UdTdT-3′; SOX2 5′-CCAAGACGCUCAUGAAGAAUU
dTdT-3′ and NANOG 5′-CGUGUGAAGAUGAGUGAAA
UUdTdT-3′. All siRNAs were purchased from Sigma.
siRNA sequence used for DIO2 was purchased from
Dharmacon (product code J-011171-09-0002).
Flow cytometry
Cells were fixed in 4% paraformaldehyde and permeabilised
with 0.1% Triton X-100. Cells were labelled with anti-DIO2
1:10 (Abcam, cat. no ab135711) and secondary antibody
Alexa Fluor 488 1:500 (Life Technologies). Controls
included IgG isotype antibody (Dako) and secondary anti-
body only. Cells were analysed using Attune NxT Flow
Cytometer (Thermo Fisher Scientific).
RNA-Seq analysis
Total RNA was extracted from cells using Ribozol™ RNA
Extraction Reagent (Amresco) following manufacturer’s
instructions. RNA-Seq library construction and sequencing
was performed at Otogenetics Corporation (Atlanta, USA)
according to standard protocols. Resulting RNA-Seq fastq
reads were aligned to Hg19 (GRCh37) using STAR [58]
and mapped to genes using HTSeq counts (http://htseq.rea
dthedocs.io/en/master/count.html). Differential expression
analysis was performed on triplicate samples using DESeq2
[59]. Genes with an adjusted p-value ≤ 0.01 were taken
forward for fold-change analysis. All heatmaps were gen-
erated using R3.4.2. Venn diagrams of overlapping gene
lists were created using the Intervene Tool [60]. Data was
deposited in GEO (GSE117193).
Statistical analysis
For real time PCR studies, two-tailed paired t-test was used
to determine statistical significance at a level of p < 0.05.
Patient survival was analysed using the Kaplan–Meier
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method with t-test and log-rank and testing, and multi-
variate analysis was performed using the Cox proportional
hazards model. All tests were undertaken using SPSS ver-
sion 11.0 computer software (SPSS, Inc.). All tests were
two-sided and a p value of <0.05 was taken to indicate
statistical significance.
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